Two Sigma Advisers
LRMR icon

Two Sigma Advisers’s Larimar Therapeutics LRMR Stock Holding History

Two Sigma Advisers’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-89,124
Closed -$340K – 1209
2025
Q4 		$340K Sell
89,124
-163,247
-65% -$635K ﹤0.01% 1941
2025
Q3 		$815K Sell
252,371
-894,553
-78% -$3.35M ﹤0.01% 1563
2025
Q2 		$3.31M Buy
1,146,924
+752,900
+191% +$1.74M 0.01% 896
2025
Q1 		$847K Buy
394,024
+327,000
+488% +$1.03M ﹤0.01% 1544
2024
Q4 		$259K Sell
67,024
-30,100
-31% -$199K ﹤0.01% 2036
2024
Q3 		$636K Sell
97,124
-35,000
-26% -$281K ﹤0.01% 1605
2024
Q2 		$958K Sell
132,124
-61,300
-32% -$469K ﹤0.01% 1571
2024
Q1 		$1.47M Buy
193,424
+84,100
+77% +$655K ﹤0.01% 1383
2023
Q4 		$497K Sell
109,324
-49,900
-31% -$168K ﹤0.01% 1926
2023
Q3 		$629K Sell
159,224
-63,500
-29% -$240K ﹤0.01% 1707
2023
Q2 		$697K Sell
222,724
-22,300
-9% -$91K ﹤0.01% 1682
2023
Q1 		$1.11M Buy
245,024
+110,500
+82% +$577K ﹤0.01% 1584
2022
Q4 		$556K Buy
134,524
+59,800
+80% +$204K ﹤0.01% 1840
2022
Q3 		$239K Buy
+74,724
New +$187K ﹤0.01% 2147
2022
Q2 		– Sell
-13,998
Closed -$57K – 2788
2022
Q1 		$57K Sell
13,998
-14,200
-50% -$92.9K ﹤0.01% 2570
2021
Q4 		$304K Sell
28,198
-4,700
-14% -$52.3K ﹤0.01% 2138
2021
Q3 		$379K Buy
+32,898
New +$395K ﹤0.01% 2025
2021
Q2 		– Sell
-11,689
Closed -$171K – 2584
2021
Q1 		$171K Buy
11,689
+1,900
+19% +$34.5K ﹤0.01% 2379
2020
Q4 		$210K Buy
+9,789
New +$196K ﹤0.01% 2154
2020
Q3 		– Sell
-13,496
Closed -$173K – 2538
2020
Q2 		$173K Sell
13,496
-4,362
-24% -$50.8K ﹤0.01% 2280
2020
Q1 		$165K Sell
17,858
-2,025
-10% -$26.6K ﹤0.01% 2218
2019
Q4 		$265K Hold
19,883
– – ﹤0.01% 2101
2019
Q3 		$176K Buy
19,883
+4,800
+32% +$52.6K ﹤0.01% 2066
2019
Q2 		$215K Buy
15,083
+8,066
+115% +$215K ﹤0.01% 2111
2019
Q1 		$231K Buy
7,017
+4,450
+173% +$228K ﹤0.01% 2074
2018
Q4 		$152K Buy
2,567
+1,375
+115% +$136K ﹤0.01% 2178
2018
Q3 		$167K Buy
+1,192
New +$145K ﹤0.01% 2107
2015
Q2 		– Sell
-458
Closed -$218K – 1989
2015
Q1 		$218K Buy
+458
New +$217K ﹤0.01% 1711

Other funds holding LRMR

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Two Sigma Advisers's LRMR Position: Q1 2026 in Review

Two Sigma Advisers sold out of Larimar Therapeutics (LRMR) in Q1 2026, closing a stake of 89,124 shares — an estimated $340K sold.

Two Sigma Advisers first reported a position in LRMR in Q1 2015 and held it in 28 quarters. The position peaked at $3.31M in Q2 2025. 162 funds tracked by Wall St. Rank hold LRMR as of Q1 2026.

  • Two Sigma Advisers reported no remaining Larimar Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 89,124 Larimar Therapeutics shares in Q1 2026, an estimated $340K.
  • Two Sigma Advisers first reported a position in Larimar Therapeutics in Q1 2015 and held it in 28 quarters.
  • Two Sigma Advisers's Larimar Therapeutics position peaked at $3.31M in Q2 2025.
  • 162 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.